Genetic predictors of thyroid cancer outcome

European Journal of Endocrinology

Volumn 174, Issue 4, 2016, Pages R117-R126

  Tavares, Catarina ^a,b   Melo, Miguel ^a,c,d   Cameselle Teijeiro, Jose Manuel ^e   Soares, Paula ^a,b   Sobrinho Simões, Manuel ^a,b,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RET PROTEIN, HUMAN; TUMOR MARKER;

BINDING SITE; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; MOLECULAR DYNAMICS; MORPHOLOGY; ONCOGENE; ONCOGENE RAS; OUTCOME ASSESSMENT; PAX8 GENE; PPAR GAMMA GENE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PTC GENE; RET GENE; REVIEW; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; ENDOCRINE GLAND NEOPLASMS; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; PROGNOSIS; RISK FACTOR; THYROID NEOPLASMS;

BIOMARKERS, TUMOR; ENDOCRINE GLAND NEOPLASMS; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; RISK FACTORS; THYROID NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84962511111     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0605     Document Type: Review

References (94)

1. Eloy C, Santos J, Cameselle-Teijeiro J, Soares P & Sobrinho-Simoes M. TGF-b/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Archiv 2012 460 587-600. (doi:10.1007/s00428-012-1234-y)
2. Rosai JD, Frable WJ & Tallini G. In Tumors of the Thyroid & Parathyroid Glands. Chapter 9, pp 500-530. American Registry of Pathology: Washington DC, 2014.
3. Soares P, Celestino R, Melo M, Fonseca E & Sobrinho-Simoes M. Prognostic biomarkers in thyroid cancer. Virchows Archiv 2014 464 333-346. (doi:10.1007/s00428-013-1521-2)
4. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014 159 676-690. (doi:10.1016/ j.cell.2014.09.050)
5. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 2005 446 589-595. (doi:10.1007/s00428-005-1236-0)
6. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P et al. PAX8-PPARg rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 213-220. (doi:10.1210/jc.2005-1336)
7. Nikiforov YE & Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nature Reviews. Endocrinology 2011 7 569-580. (doi:10.1038/nrendo.2011.142)
8. Eloy C, Santos J, Soares P & Sobrinho-Simoes M. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv 2011 459 265-276. (doi:10.1007/ s00428-011-1133-7)
9. Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE & Nikiforov YE. PAX8/PPARg rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 2014 24 1369-1374. (doi:10.1089/thy.2014.0067)
10. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G & Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987 328 170-172. (doi:10.1038/328170a0)
11. Romei C & Elisei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Frontiers in Endocrinology 2012 3 54. (doi:10.3389/fendo.2012.00054)
12. Soares P, Fonseca E, Wynford-Thomas D & Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? Journal of Pathology 1998 185 71-78. (doi:10.1002/(SICI)1096-9896(199805)185:1! 71::AID-PATH42O3.0.CO;2-S)
13. Thomas GABH, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. Journal of Clinical Endocrinology and Metabolism 1999 84 4232-4238. (doi:10.1210/jcem.84.11.6129)
14. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 2002 13 3-16. (doi:10.1385/EP:13:1:03)
15. Mochizuki KKT, Nakazawa T, Iwashina M, Kawasaki T, Nakamura N, Yamane T, Murata S, Ito K, Kameyama K, Kobayashi M et al. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology 2010 57 444-450. (doi:10.1111/j.1365-2559.2010.03646.x)
16. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 1997 57 1690-1694.
17. Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB & Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery 1999 125 46-52. (doi:10.1016/S0039-6060(99)70287-4)
18. Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J & Soares P. Intragenic mutations in thyroid cancer. Endocrinology and Metabolism Clinics of North America 2008 37 333-362, viii. (doi:10.1016/j.ecl.2008.02.004)
19. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG & Leite V. Expression of PAX8-PPARg1 rearrangements in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 2002 87 3947-3952. (doi:10.1210/jcem. 87.8.8756)
20. Howell GM, Hodak SP & Yip L. RAS mutations in thyroid cancer. Oncologist 2013 18 926-932. (doi:10.1634/theoncologist.2013-0072)
21. Garcia-Rostan G, Zhao H, Camp RL, PollanM, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 2003 21 3226-3235. (doi:10.1200/JCO.2003. 10.130)
22. Jang EK, Song DE, Sim SY, Kwon H, Choi YM, Jeon MJ, Han JM, Kim WG, Kim TY, Shong YK et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. Thyroid 2014 24 1275-1281. (doi:10.1089/thy.2014.0053)
23. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 2012 22 683-689. (doi:10.1089/thy.2011.0261)
24. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology 2003 120 71-77. (doi:10.1309/ND8D9LAJTRCTG6QD)
25. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. Mutations of the BRAF gene in human cancer. Nature 2002 417 949-954. (doi:10.1038/ nature00766)
26. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE & Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 2005 65 4238-4245. (doi:10.1158/0008-5472.CAN-05-0047)
27. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 2005 115 1068-1081. (doi:10.1172/JCI200522758)
28. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 2003 88 5399-5404. (doi:10.1210/jc.2003-030838)
29. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 2007 246 466-470 (discussion 470-471). (doi:10.1097/SLA.0b013e318148563d)
30. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 2003 63 4561-4567. (doi:10.1111/j. 1365-2265.2006.02605.x)
31. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology 2006 65 364-368. (doi:10.1111/j.1365-2265.2006.02605.x)
32. Xing M. BRAF mutation in thyroid cancer. Endocrine-Related Cancer 2005 12 245-262. (doi:10.1677/erc.1.0978)
33. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 2003 88 4393-4397. (doi:10.1210/jc.2003-030305)
34. Oler G & Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009 115 972-980. (doi:10.1002/ cncr.24118)
35. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A & Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median followup study. Journal of Clinical Endocrinology and Metabolism 2008 93 3943-3949. (doi:10.1210/jc.2008-0607)
36. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, NistalM & Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of NaC/IK targeting to the membrane. Endocrine-Related Cancer 2006 13 257-269. (doi:10.1677/erc.1.01119)
37. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 2006 13 455-464. (doi:10.1677/ erc.1.01086)
38. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L & Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clinical Endocrinology 2004 61 239-243. (doi:10.1111/j. 1365-2265.2004.02089.x)
39. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N & Yamashita S. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. International Journal of Cancer 2007 120 196-200. (doi:10.1002/ijc.22290)
40. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Journal of Clinical Endocrinology and Metabolism 2012 97 4390-4398. (doi:10.1210/jc.2012-1775)
41. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 2013 309 1493-1501. (doi:10.1001/jama.2013.3190)
42. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Maximo V et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Current Genomics 2011 12 609-617. (doi:10.2174/138920211798120853)
43. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 2007 92 2840-2843. (doi:10.1210/jc.2006-2707)
44. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer 2008 15 511-520. (doi:10.1677/ERC-07-0130)
45. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation 2011 121 4700-4711. (doi:10.1172/JCI46382)
46. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S et al. Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine 2013 368 623-632. (doi:10.1056/NEJMoa1209288)
47. Capezzone M, Cantara S, Marchisotta S, Busonero G, Formichi C, Benigni M, Capuano S, Toti P, Pazaitou-Panayiotou K, Caruso G et al. Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2011 96 E1852-E1856. (doi:10.1210/jc. 2011-1003)
48. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L et al. Frequency of TERT promoter mutations in human cancers. Nature Communications 2013 4 2185. (doi:10.1038/ncomms3185)
49. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 2013 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
50. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 2013 20 603-610. (doi:10.1530/ERC-13-0210)
51. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013 339 959-961. (doi:10.1126/science.1230062)
52. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2014 99 E754-E765. (doi:10.1210/jc.2013-3734)
53. de Vries MM, Celestino R, Castro P, Eloy C, Maximo V, van der Wal JE, Plukker JT, Links TP, Hofstra RM, Sobrinho-Simoes M et al. RET/PTC rearrangement is prevalent in follicular Hurthle cell carcinomas. Histopathology 2012 61 833-843. (doi:10.1111/j.1365-2559.2012. 04276.x)
54. Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. British Journal of Cancer 2005 92 1892-1898. (doi:10.1038/sj.bjc.6602547)
55. Maximo V, Lima J, Prazeres H, Soares P & Sobrinho-Simoes M. The biology and the genetics of Hurthle cell tumors of the thyroid. Endocrine-Related Cancer 2012 19 R131-R147. (doi:10.1530/ ERC-11-0354)
56. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014 33 4978-4984. (doi:10.1038/onc.2013.446)
57. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A & Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology 2015 172 403-413. (doi:10.1530/EJE-14-0837)
58. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology 2014 32 2718-2726. (doi:10.1200/JCO.2014. 55.5094)
59. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Molecular and Cellular Endocrinology 2015 399 288-295. (doi:10.1016/j. mce.2014.10.019)
60. Sampson E, Brierley JD, Le LW, Rotstein L & Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007 110 1451-1456. (doi:10.1002/cncr.22956)
61. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2014 99 E1130-E1136. (doi:10.1210/jc.2013-4048)
62. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ & Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005 436 720-724. (doi:10.1038/nature03890)
63. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci Met al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015 348 1036-1039. (doi:10.1126/science.aab0015)
64. Preto A, Singhrao SK, Haughton MF, Kipling D, Wynford-Thomas D & Jones CJ. Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy. Oncogene 2004 23 4136-4145. (doi:10.1038/sj.onc. 1207564)
65. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM & Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife 2015 4 e07918. (doi:10.7554/eLife.07918)
66. Melo M, da Rocha AG, Vinagre J, Sobrinho-Simoes M & Soares P. Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? Journal of Clinical Oncology 2015 33 667-668. (doi:10.1200/JCO.2014.59.4614)
67. Levine AJ & Oren M. The first 30 years of p53: growing ever more complex. Nature Reviews. Cancer 2009 9 749-758. (doi:10.1038/ nrc2723)
68. Lane D & Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harbor Perspectives in Biology 2010 2 a000893. (doi:10.1101/cshperspect.a000893)
69. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N & Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Research 1992 52 1369-1371.
70. Ito T, Seyama T,Mizuno T, Tsuyama N, Hayashi Y, Dohi K, Nakamura N & Akiyama M. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Japanese Journal of Cancer Research 1993 84 526-531. (doi:10.1111/j.1349-7006.1993.tb00171.x)
71. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 1993 91 1753-1760. (doi:10.1172/JCI116385)
72. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 1993 91 179-184. (doi:10.1172/JCI116168)
73. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T & Machinami R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. American Journal of Surgical Pathology 1993 17 375-381. (doi:10.1097/00000478-199304000-00008)
74. Soares P, Cameselle-Teijeiro J & Sobrinho-Simoes M. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology 1994 24 205-210. (doi:10.1111/j.1365-2559.1994.tb00511.x)
75. Park KY, Koh JM, Kim YI, Park HJ, Gong G, Hong SJ & Ahn IM. Prevalences of Gsa, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clinical Endocrinology 1998 49 317-323. (doi:10.1046/j.1365-2265. 1998.00515.x)
76. Farid P, Gomb SZ, Peter I & Szende B. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis. Neoplasma 2001 48 299-301.
77. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roher HD, Williams ED & Wynford-Thomas D. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 1991 6 1693-1697.
78. Nikiforov YE, Nikiforova MN, Gnepp DR & Fagin JA. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 1996 13 687-693.
79. Nikiforova MN, Wald AI, Roy S, Durso MB & Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2013 98 E1852-E1860. (doi:10.1210/jc.2013-2292)
80. Ruter A, Dreifus J, JonesM, Nishiyama R & Lennquist S. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery 1996 120 1046-1050. (doi:10.1016/S0039-6060(96)80053-5)
81. Putti TC & Bhuiya TA. Mixed columnar cell and tall cell variant of papillary carcinoma of thyroid: a case report and review of the literature. Pathology 2000 32 286-289.
82. Kleer CG, Giordano TJ & Merino MJ. Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma. Modern Pathology 2000 13 742-746. (doi:10.1038/modpathol.3880129)
83. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruiz-Ponte C, Soares P & Sobrinho-Simoes M. Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. American Journal of Clinical Pathology 2009 131 134-142. (doi:10.1309/AJCP7ULS0VSISBEB)
84. Nakazawa T, Celestino R, Machado JC, Cameselle-Teijeiro JM, Vinagre J, Eloy C, Benserai F, Lameche S, Soares P & Sobrinho-Simoes M. Cribriform-morular variant of papillary thyroid carcinoma displaying poorly differentiated features. International Journal of Surgical Pathology 2013 21 379-389. (doi:10.1177/1066896912473355)
85. Pita JM, Figueiredo IF, Moura MM, Leite V & Cavaco BM. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2014 99 E497-E507. (doi:10.1210/ jc.2013-1512)
86. Quiros RM, Ding HG, Gattuso P, Prinz RA & Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005 103 2261-2268. (doi:10.1002/cncr.21073)
87. Evans JJ, Crist HS, Durvesh S, Bruggeman RD & Goldenberg D. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma. Cancer Biology & Therapy 2012 13 776-781. (doi:10.4161/cbt.20560)
88. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierotti MA & Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. American Journal of Surgical Pathology 1994 18 1054-1064. (doi:10.1097/00000478-199410000-00009)
89. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A & Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997 14 729-740. (doi:10.1038/sj.onc. 1200887)
90. DeLellis RA, Lloyd RV, Heitz PU & Eng C. In WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004.
91. Cameselle-Teijeiro J, Rodr?éguez-Peérez I, Celestino R, Eloy C, Piso Neira I, Abdulkader Nallib I, Soares P & Sobrino-Simões M. Hobnail/ micropapillary variant of papillary thyroid carcinoma: Evidence of progression to undifferentiated carcinoma with molecular analysis. Virchows Archiv 2015 467 (Supplement 1) S69.
92. Mazeh H. MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules. Oncologist 2012 17 1032-1038. (doi:10.1634/ theoncologist.2012-0013)
93. Jendrzejewski J, He H, Radomska HS, Li W, Tomsic J, Liyanarachchi S, Davuluri RV, Nagy R & de la Chapelle A. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoDing RNA gene of tumor suppressor type. PNAS 2012 109 8646-8651. (doi:10.1073/pnas.1205654109)
94. Kentwell J, Gundara JS & Sidhu SB. NoncoDing RNAs in endocrine malignancy. Oncologist 2014 19 483-491. (doi:10.1634/theoncologist. 2013-0458)